|
|
||||||||
Department of Neurology, Johns Hopkins University School of Medicine, and Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
When BALB/c and SJL mice are infected with the encephalitic alphavirus Sindbis virus (SV), both animals initiate similar CNS mononuclear cell inflammatory responses (9). This CNS inflammation results in the clearance of infectious virus from the brains and spinal cords of these two hosts with identical kinetics (9). Yet despite their equivalent antiviral responses, SJL mice develop prolonged CNS inflammation and immune-mediated paralysis during infection, while BALB/c mice terminate inflammation and remain asymptomatic throughout the disease (9). As a result, the present study was undertaken to explore how the same stimulus could elicit such divergent immunologic effects on the host. Attention was focused on lymphocyte function and survival in the brains of these animals, since previous data have shown that the proliferation and IL-2 production of T cells isolated from the CNS of SV-infected BALB/c mice were abrogated through a mechanism that involved the cells being exposed to inhibitory substances within the brain (8), and because apoptosis has recently been shown to be an important means of down-regulating pathologic inflammation in the brain (10, 11). The present data show that CNS lymphocytes from SJL mice perform several important effector functions more readily than do cells that have been isolated from the brains of BALB/c mice. These cells also appear to be less susceptible to apoptosis, possibly through a mechanism that involves limiting the expression of the proapoptotic gene, bax (12). Furthermore, parallel experiments show that peripheral lymphocytes from SJL mice are less susceptible than cells from BALB/c mice to the inhibitory effects that purified brain-derived gangliosides exert on these same T cell effector functions. These complex membrane glycosphingolipids are highly enriched in the brain and are known to inhibit both the proliferation and the production of Th1-associated cytokines in T cells that have been activated in vitro (13). While brain-derived gangliosides up-regulate bax mRNA expression in lymphocytes from both strains, they do so to a much lesser degree in cells from SJL mice. Taken together, these findings indirectly imply that the differences in the degree to which lymphocytes resist the immunoregulatory effects of CNS gangliosides may explain why the effector responses of lymphocytes that have been isolated from the brains of these two hosts are different. Whether the susceptibility of lymphocytes to the regulatory effects of gangliosides has anything to do with the risk of the host developing immune-mediated neurologic disease remains unproven. However, since it is proposed that an increased responsiveness of lymphocytes to the local regulatory effects of CNS gangliosides may help to protect a host from such disorders, studying how these lipids exert their effects at a molecular level could shed further light on the pathogenesis of immune-mediated CNS disease.
| Materials and Methods |
|---|
|
|
|---|
BALB/cJ and SJL/J mice of 3 to 4 wk of age (The Jackson Laboratory, Bar Harbor, ME) were maintained as colonies according to institutional guidelines for animal care. All animal procedures were performed under methoxyflurane anesthesia. To induce encephalitis, mice were injected intracerebrally with 1000 plaque-forming units of SV that were suspended in 0.02 ml of HBSS (Life Technologies, Grand Island, NY). Some animals were injected i.v. with 50 mg/kg of 5-bromo-2'-deoxyuridine (BrdU) (Sigma, St. Louis, MO) at various stages of infection. These animals were euthanized several hours later and perfused extensively with HBSS; brain and spleen tissue was frozen at -70°C for subsequent immunocytochemical staining (see below). In other experiments, mononuclear cells were isolated from the brains of SV-infected animals for in vitro culture, FACS analysis, or the isolation of total cellular mRNA (see below). Spleen-derived mononuclear cells and perfused brain tissue were isolated from uninfected animals of both strains for use as responder cells in various in vitro assays and for preparing brain tissue supernatants, respectively (see below).
Immunocytochemical detection of BrdU-labeled cells in tissue sections
As described above, 10-µ frozen sections of brain and spleen tissue were prepared from SV-infected animals that had been labeled in vivo with BrdU. The slides were stained with a biotinylated primary anti-BrdU Ab according to the manufacturers instructions using a commercial BrdU Staining Kit (Oncogene Research Products, Cambridge, MA). A total of 10 slides per animal from three BALB/c and three SJL mice were prepared and stained at each stage of infection. A single section of spleen from each animal was also stained to confirm that the BrdU had been adequately injected into all recipients. The slides of brain tissue were examined by light microscopy in a blinded manner, and the total number of BrdU-positive cells per focus of inflammation was counted. A minimum of 25 inflammatory foci were examined for each host strain at each stage of infection. In this way, the mean and SD of the number of BrdU-positive cells per inflammatory focus was determined. While the average number and size of inflammatory foci tended to increase over time in SV-infected animals, there were no differences found in these parameters between BALB/c and SJL mice at each timepoint after the number of BrdU-positive cells had been counted and the slides unblinded (data not shown).
Isolation of tissue-derived lymphocytes
A complete description of the technique that was used to isolate inflammatory cells from neural tissue has been reported previously (14). Briefly, each perfused brain was gently homogenized in HBSS containing 0.1% collagenase D (Boehringer Mannheim, Indianapolis, IN) and 10 µg/ml of DNase I (Sigma). Tissue fragments were removed by sedimentation at unit gravity, and the remaining suspension was centrifuged over a modified density gradient that had been prepared by mixing 3 parts Ficoll-Paque (Pharmacia, Piscataway, NJ) with 1 part RPMI 1640 (Life Technologies). Debris was retained at the gradient interface, while intact cells were recovered from within the gradient medium. Spleen homogenates were centrifuged over Lympholyte-M murine density separation medium (Cedarlane Laboratories, Hornby, Canada), and viable lymphocytes were recovered from the gradient interface.
Preparation of supernatants from brain tissue homogenates
Homogenates of uninfected brain tissue from both strains of mice were prepared to compare the immunoregulatory properties of normal brain constituents in vitro. Each perfused brain was homogenized directly in 10 ml of RPMI 1640 containing 10% FCS (Life Technologies). Clarified supernatants were then created by centrifuging the homogenates at 15,000 x g for 20 min. These supernatants were used directly as 0 to 10% (v/v) solutions in vitro.
In vitro culture experiments
Isolated lymphocytes were washed in HBSS and resuspended in RPMI
1640 containing 10% FCS. Cells were typically cultured in 96-well
microtiter plates (2 x 105 cells/well in a final
volume of 200 µl) in media containing 50 ng/ml of PMA (Calbiochem, La
Jolla, CA) and 2 µg/ml of ionomycin (Calbiochem). Quadruplicate wells
were prepared for each condition in each experiment, and the mean and
SD values of each measured value are shown in the figures.) For
some of the brain-derived inflammatory cells, sterile
[3H]TdR (1 µCi/well, 5 Ci/mmol) (DuPont-New England
Nuclear, Boston, MA) was added during the last 16 h of either 24-,
48-, or 72-h incubations; plates were harvested for scintillation
counting using a microplate harvesting system (Skatron Instruments,
Sterling, VA). The difference between the incorporated cpm in the wells
of stimulated and unstimulated cells (
cpm) was determined at each of
these intervals. In other plates, culture supernatants were collected
after 24 and 48 h of stimulation for the measurement of IL-2 and
IL-4 production using commercially available mouse cytokine ELISA kits
(Endogen, Cambridge, MA). To insure that any differences could not be
attributed to discrepancies in cell viability, readouts for both
proliferation and cytokine production were normalized to the values
that had been obtained per 105 viable cells counted at each
timepoint.
Spleen cells from uninfected mice of both strains were stimulated as described above. In some assays, increasing concentrations of brain supernatant were added, and the amount of proliferation compared with untreated cells was measured by [3H]TdR incorporation after 72 h of culture. In other experiments, various concentrations of purified brain-derived gangliosides (Calbiochem) were added to the culture media. The ganglioside preparations were >98% pure by TLC and contained 21% GM1, 40% GD1a, 16% GD1b, and 19% GT1b according to the manufacturer. Here, cellular proliferation was measured at 72 h by [3H]TdR incorporation, IL-2 production was measured in culture supernatants at 24 and 48 h by ELISA (Endogen), cell viability was determined after 24, 48, and 72 h by trypan blue exclusion, and total cellular mRNA was extracted after 24, 48, and 72 h for RT-PCR analysis (see below). Again, readouts for both proliferation and cytokine production were normalized to values that had been obtained per 105 viable cells at each timepoint to insure that any differences could not be attributed to discrepancies in cell viability.
FACS analysis of tissue-derived lymphocytes
To look for evidence of apoptosis, FACS analysis was performed on brain-derived inflammatory cells that had been isolated from SV-infected animals. Here, cells were stained using a combination of FITC-annexin V and propidium iodide (PI) according to the protocol supplied by the manufacturer (R&D Systems, Minneapolis, MN). The percentage of preapoptotic cells (annexin V-positive, PI-negative) and apoptotic or necrotic cells (annexin V-positive, PI-positive) in each population was determined using a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA).
RT-PCR quantitation of relative intracellular bax mRNA levels
Total cellular RNA was extracted from brain-derived lymphocytes that had been isolated directly from SV-infected animals or from peripheral lymphocytes that were cultured in the presence of brain-derived gangliosides for various intervals as described above to detect bax-specific mRNAs by RT-PCR and to quantitate their levels relative to the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. Briefly, 1 µg of total cellular RNA was reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (Life Technologies) in a 25-µl reaction volume containing 50 mM Tris-HCl (pH 8.3), 20 mM KCl, 10 mM MgCl2, 5 mM DTT, 1 mM of each deoxynucleotide triphosphate, and 20 µg/ml oligo(dT) for 40 min at 42°C. The reaction mixture was diluted to 1/8 with distilled water after first-strand cDNA synthesis, and 10 µl of the diluted product was used in each PCR. PCRs contained 200 µM of each deoxynucleotide triphosphate, 1 µM of each specific primer, buffer as supplied by the manufacturer, and 2.5 U of Taq DNA polymerase (Boehringer Mannheim). The sequences for the primers and probes used in these experiments have been published elsewhere (15). PCR was performed at a cycle number that ensured that amplification was occurring in a linear range. A 9600 thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) was used for all of the PCRs. Serial dilutions of a positive control for bax and GAPDH were amplified at 25, 30, and 35 cycles generating standard curves to insure a fixed relationship between the initial RNA input and the densitometric readout. A portion of each PCR reaction product was electrophoresed through a 1.2% agarose gel and transferred to a Hybond-N+ membrane (Amersham, Arlington Heights, IL) using standard blotting techniques. Southern transfers were probed with labeled internal bax-specific oligonucleotides and visualized using the enhanced chemiluminescence chemiluminescent detection system (Amersham). Autoradiograms were scanned using a laser densitometer (Molecular Dynamics, Sunnyvale, CA). The relative amount of bax-specific mRNA was determined by dividing the measured intensity of each band with that of the GAPDH gene from the same sample, thus controlling for the amount of mRNA that was transcribed in each RT reaction.
| Results |
|---|
|
|
|---|
Unlike BALB/c mice that remain asymptomatic, SJL mice develop
immune-mediated paralysis during acute SV encephalitis (9). To
understand how the same infection could result in such divergent
immunologic effects on the host, qualitative differences between the
CNS inflammatory response of these two strains were sought. In
particular, the capacity of brain-derived lymphocytes to survive and
exert their various effector functions was investigated, since a
previous study has shown that both the proliferation and the IL-2
production of T cells that have been isolated from the CNS of
SV-infected BALB/c mice are impaired (8). To determine whether similar
local immunoregulatory effects were being exerted in the brains of SJL
mice, a BrdU labeling technique was used to compare the proliferation
of CNS inflammatory cells in these two strains during acute SV
infection. These studies showed that, while most of the inflammatory
cells infiltrating the brain were not proliferating (Fig. 1
A), SJL mice had more
BrdU-positive cells per inflammatory focus than did BALB/c mice (Fig. 1
B). In contrast, BrdU staining was quantitatively similar
in the spleens of both host strains at all stages of infection (data
not shown). When lymphocytes were isolated from the brains of infected
animals and cultured in vitro, those from SJL mice exhibited measurable
[3H]TdR incorporation over time, while those from BALB/c
mice did not (Fig. 1
C). To insure that these in vitro
results could not be explained by differences in the viabilities of
these two populations, all
cpm measurements were normalized to
counts per 105 viable cells. Together, these findings
support the hypothesis that the inflammation in the brains of SJL mice
is regulated differently than the inflammation in the brains of BALB/c
mice during acute SV infection.
|
To determine whether the lymphocytes isolated from the
brains of SJL mice during SV infection could respond more readily in
other ways than cells from the brains of BALB/c mice, the
cytokine-producing capacity of these two populations was studied in
vitro. In bulk culture, lymphocytes from the brains of SJL mice
produced more IL-2 per 105 viable cells than did
lymphocytes from the brains of BALB/c mice (Fig. 2
). In contrast, levels of the
Th2-associated cytokine, IL-4, were not different between the two
populations (data not shown). Thus, at least during SV infection,
lymphocytes that were isolated from the brains of SJL mice appeared
more capable of another response than did cells from the brains of
BALB/c mice.
|
Apoptosis has recently been proposed as the mechanism that
down-regulates inflammation in the brain during EAE remissions (10, 11). Furthermore, apoptotic signaling through the Fas/Fas ligand (FasL)
pathway augments the development of this disease and may promote the
death of oligodendrocytes in MS (7, 16, 17). When analyzed in the
present system by flow cytometry, fewer lymphocytes from the brains of
SJL mice exhibited annexin V binding, which is a cell membrane event
that begins early in apoptosis, compared with cells from the brains of
BALB/c mice (Fig. 3
). There was also less
total cellular DNA fragmentation found in SJL-derived cells compared
with BALB/c-derived cells when analyzed on ethidium bromide-stained
agarose gels (data not shown). It is likely that this decreased rate of
lymphocyte cell death accounts for the prolonged inflammation that is
found in the brains of SV-infected SJL mice (9). However, while
lymphocytes from the brains of SJL mice appeared less susceptible to
apoptosis, parallel FACS analyses showed that these cells did not
express different levels of either Fas or FasL compared with cells from
the brains of BALB/c mice (data not shown). As a result, the
mechanism(s) through which these cells induce symptomatic neurologic
disease in this setting remain unknown.
|
|
To explore whether different degrees of responsiveness to
the local immunoregulatory effects exerted within the CNS might explain
why lymphocytes from the brains of these two animals behaved
differently in vitro, clarified supernatants that had been prepared
from homogenates of normal brain tissue were added to cultures of
peripheral lymphocytes that were stimulated in vitro. In assays of
mitogen-induced proliferation, SJL brain supernatant had less of an
inhibitory effect on the proliferation of SJL cells compared with the
effect of equal concentrations of BALB/c brain supernatant on BALB/c
cells (Fig. 5
A). To understand
the basis for this difference, BALB/c brain supernatants were tested on
SJL lymphocytes and vice versa. While SJL brain supernatant could
easily inhibit the proliferation of BALB/c cells, SJL lymphocytes were
relatively resistant to the antiproliferative effects of the BALB/c
brain supernatant (Fig. 5
B). This finding strongly suggests
that the response of the cells, and not the content of the brain
supernatant, accounts for the differences observed. Proliferation was
calculated in these assays as incorporated cpm per 105
viable cells to eliminate the possibility that discrepancies in the
viability of responder cells might explain this effect. When these in
vitro data are extrapolated, it seems more likely that the greater
numbers of inflammatory cells in the brains of SV-infected SJL mice
could incorporate BrdU because they were more resistant to the
antiproliferative effects of the substances found within the brain,
rather than the local immunologic environment in the brains of these
mice being intrinsically less capable of inhibiting lymphocyte
proliferation.
|
It has been shown that the inhibitory activity of BALB/c
brain supernatant is due in large part to its abundant ganglioside
content (8). Therefore, the effects of purified brain-derived
gangliosides were compared in cultures of peripheral lymphocytes from
BALB/c and SJL mice. Like their response to the whole brain
supernatants, SJL lymphocytes were more resistant to the
antiproliferative effects of the brain-derived gangliosides than were
BALB/c cells (Fig. 6
). Because these
lipids also block the production of IL-2 by activated T cells through a
mechanism that is separate from their antiproliferative effects (13),
this event was examined in peripheral lymphocytes from these two host
strains as well. When assayed in culture supernatants, brain-derived
gangliosides inhibited the production of IL-2 by activated BALB/c
lymphocytes; however, the production of IL-2 by SJL cells was not
altered to any appreciable degree (Fig. 7
). The divergent effects of CNS
gangliosides on the proliferation and IL-2 production by these two
lymphocyte populations could not be explained by any selective effects
on cell viability, since both responses were carefully normalized to a
fixed number of viable cells in each assay. This distinction is
important, because the brain-derived gangliosides did in fact
accelerate the rate of activation-induced cell death in lymphocytes
from BALB/c cells without affecting the viability of mitogen-stimulated
SJL cells (Fig. 8
). These lipids also
caused a preferential induction of bax mRNA in BALB/c lymphocytes over
time (Fig. 9
). Taken together, the
variable effects that brain-derived gangliosides exert on peripheral
lymphocytes from BALB/c and SJL mice closely predict the degree to
which CNS lymphocytes from these two mice respond.
|
|
|
|
| Discussion |
|---|
|
|
|---|
It is likely that multiple factors influence the susceptibility of different rodent strains to immune-mediated CNS disorders. However, one important variable is the capacity of lymphocytes to exert their effector functions within the brain; in one study, cells from mice that were deficient in either Fas or FasL could accumulate in the CNS but could not induce paralysis during EAE (7). A previous study using the current encephalitis model system showed that T cells that were isolated from the brains of SV-infected BALB/c mice had impaired effector responses resulting from their exposure to gangliosides within the brain (8). Since SJL mice develop prolonged inflammation and immune-mediated paralysis with acute SV infection, and BALB/c mice display resistance (9), the current experiments arose from the hypothesis that the lymphocytes recruited into the brains of these mice somehow resisted the local inhibitory effects of gangliosides, thereby retaining some capacity to induce neurologic disease. These data confirm that SJL lymphocytes resist the inhibitory effects of brain-derived gangliosides in vitro and exert more robust effector responses within the brain in vivo. However, these findings do not prove that any of these effects are in any way responsible for the induction of neurologic symptoms in SV-infected SJL mice. Furthermore, such results argue against a role for the Fas/FasL pathway as an effector of this process. Proof of a cause-and-effect relationship between these data and disease susceptibility will require either a more complete understanding of how gangliosides alter T cell function at the molecular level and the capacity to block their effects pharmacologically, or the generation of mice that are deficient in the enzymes that regulate the synthesis of CNS gangliosides or the gene product(s) that control lymphocyte responses to gangliosides. In lieu of such advances, however, improving the strength of the correlation between the susceptibility of lymphocytes to gangliosides in vitro and resistance to immune-mediated CNS disease in vivo will continue using peripheral lymphocytes from other susceptible and resistant rodent strains as well as from normal human controls and patients known to have MS. Furthermore, the study of other T cell responses in SV-infected BALB/c and SJL mice may clarify the mechanism(s) through which neurologic symptoms actually develop.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. David N. Irani, Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, 615 N. Wolfe Street, Baltimore, MD 21205-2179. ![]()
3 Abbreviations used in this paper: CNS, central nervous system; MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; SV, Sindbis virus; BrdU, 5-bromo-2'-deoxyuridine; PI, propidium iodide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FasL, Fas ligand. ![]()
Received for publication March 11, 1998. Accepted for publication May 14, 1998.
| References |
|---|
|
|
|---|
4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57.This article has been cited by other articles:
![]() |
A. M. Ercolini and S. D. Miller Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease J. Immunol., March 15, 2006; 176(6): 3293 - 3298. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-G. Fischer and G. Reichmann Brain Dendritic Cells and Macrophages/Microglia in Central Nervous System Inflammation J. Immunol., February 15, 2001; 166(4): 2717 - 2726. [Abstract] [Full Text] [PDF] |
||||
![]() |
, von, , , , and In Situ Tolerance within the Central Nervous System As a Mechanism for Preventing J. Exp. Med., September 18, 2000; 192(6): 871 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Walker, T. Calzascia, V. Schnuriger, N. Scamuffa, P. Saas, N. de Tribolet, and P.-Y. Dietrich The Brain Parenchyma Is Permissive for Full Antitumor CTL Effector Function, Even in the Absence of CD4 T Cells J. Immunol., September 15, 2000; 165(6): 3128 - 3135. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Rowell and D. E. Griffin The Inflammatory Response to Nonfatal Sindbis Virus Infection of the Nervous System Is More Severe in SJL Than in BALB/c Mice and Is Associated with Low Levels of IL-4 mRNA and High Levels of IL-10-Producing CD4+ T Cells J. Immunol., February 1, 1999; 162(3): 1624 - 1632. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |